FH and leiomyoma: As such, it is important not only to ensure that the surgical margins are clear on initial excision but also to closely monitor the patient over time for the development of new or recurrent leiomyomas and/or renal tumors and to consider ancillary tests for HLRCC, such as FH immunohistochemistry and germline molecular testing.